Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.5 HKD | +0.98% | +11.34% | +18.71% |
08:55am | Shanghai Henlius Biotech's Cancer Drug Gets the Nod from US FDA | MT |
Apr. 24 | Shanghai Henlius Biotech Doses 1st Patient in Fibrosis Drug Clinical Study in China | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+18.71% | 1.13B | |
-4.66% | 87.53B | |
+2.63% | 40.42B | |
-21.76% | 29.48B | |
+55.96% | 25.43B | |
-14.78% | 15.59B | |
-18.49% | 11.49B | |
-15.61% | 11.1B | |
-44.02% | 11.3B | |
+4.27% | 8.75B |
- Stock Market
- Equities
- 2696 Stock
- News Shanghai Henlius Biotech, Inc.
- Shanghai Henlius Biotech : Henlius Biotech's Second Production Line for Cancer Treatment Passes Chinese Regulator Inspection